Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
68.11-0.41 (-0.60%)
At close: 11:35 AM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close68.52
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range67.22 - 68.31
52wk Range25.29 - 68.31
1y Target EstN/A
Market Cap86.63B
P/E Ratio (ttm)21.18
Avg Vol (3m)7,511
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Is This MannKind's Last Remaining Option?
    Motley Fool2 hours ago

    Is This MannKind's Last Remaining Option?

    Should MannKind try to save itself by divesting Afrezza? Here's why this last ditch option may be no option at all.

  • Forbes6 hours ago

    EpiPen Competitor Auvi-Q To Return To Market, Promising Lower Costs For Patients

    The last time Auvi-Q was sold, it didn't lower costs. Will this time be different?

  • Reuters6 hours ago

    EpiPen rival plans return to U.S. market in first-half 2017

    Privately held drugmaker Kaleo Inc announced on Wednesday plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of next year. Auvi-Q, designed to deliver the same epinephrine drug as Mylan NV's EpiPen, was recalled from the market last year amid concerns about accuracy of the dosage delivered. Mylan has come under fire from lawmakers and consumer groups for raising the list price for a pair of EpiPens to more than $600 this year from $100 in 2007 when Mylan acquired the product.